Payment overview · 2025
General Payments
$150.80
11 reported records · 5 companies
Healthcare provider profile · identity verified
Rick J Geier, MD
Allopathic & Osteopathic Physicians|General Practice · CARRINGTON, ND · NPI 1063499804
Verified facts
What the public records show
CMS Open Payments records show Rick J Geier, MD received $150.80 in general payments during 2025 across 11 reported records.
Exact Sciences Corporation accounted for 32.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 301 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $48.77 | 32.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.10 | 25.3% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.25 | 18.1% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.87 | 13.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.81 | 10.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $150.80 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $38.10 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $34.01 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $27.25 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $24.07 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 301 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 113 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
113 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
301 | 54 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 947 | 233 |
| Metoprolol Succinate | Metoprolol Succinate | 690 | 164 |
| Levothyroxine Sodium | Levothyroxine Sodium | 576 | 119 |
| Spironolactone | Spironolactone | 504 | 129 |
| Atorvastatin Calcium | Atorvastatin Calcium | 457 | 104 |
| Losartan Potassium | Losartan Potassium | 450 | 101 |
| Amlodipine Besylate | Amlodipine Besylate | 446 | 109 |
| Prednisone | Prednisone | 406 | 262 |
| Lisinopril | Lisinopril | 400 | 112 |
| Pantoprazole Sodium | Pantoprazole Sodium | 351 | 90 |
| Omeprazole | Omeprazole | 340 | 77 |
| Estradiol | Estradiol | 309 | 74 |
| Eliquis | Apixaban | 301 | 54 |
| Furosemide | Furosemide | 271 | 59 |
| Potassium Chloride | Potassium Chloride | 262 | 46 |
| Lorazepam | Lorazepam | 255 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 228 | 57 |
| Metformin Hcl | Metformin Hcl | 219 | 54 |
| Torsemide | Torsemide | 196 | 52 |
| Famotidine | Famotidine | 189 | 42 |
| Azithromycin | Azithromycin | 186 | 137 |
| Escitalopram Oxalate | Escitalopram Oxalate | 180 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 174 | 43 |
| Allopurinol | Allopurinol | 172 | 38 |
| Gabapentin | Gabapentin | 172 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 149 | 37 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 145 | 35 |
| Cefuroxime | Cefuroxime Axetil | 134 | 104 |
| Simvastatin | Simvastatin | 131 | 36 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 125 | 24 |
| Sertraline Hcl | Sertraline Hcl | 123 | 27 |
| Meloxicam | Meloxicam | 117 | 49 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 113 | 24 |
| Ozempic | Semaglutide | 113 | 16 |
| Trazodone Hcl | Trazodone Hcl | 113 | 24 |
| Atenolol | Atenolol | 109 | 25 |
| Carvedilol | Carvedilol | 105 | 26 |
| Alprazolam | Alprazolam | 100 | 33 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 94 | 77 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 94 | 70 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 93 | 33 |
| Mounjaro | Tirzepatide | 93 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 92 | 66 |
| Tramadol Hcl | Tramadol Hcl | 92 | 38 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 83 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 81 | 16 |
| Alendronate Sodium | Alendronate Sodium | 76 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 74 | 16 |
| Warfarin Sodium | Warfarin Sodium | 73 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 70 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 68 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 67 | 11 |
| Montelukast Sodium | Montelukast Sodium | 66 | 19 |
| Hydrocortisone | Hydrocortisone | 64 | 15 |
| Celecoxib | Celecoxib | 62 | 16 |
| Synthroid | Levothyroxine Sodium | 62 | 15 |
| Fyavolv | Norethindrone Ac/Eth Estradiol | 60 | 13 |
| Bupropion Xl | Bupropion Hcl | 59 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 55 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 53 | suppressed |
| Fluconazole | Fluconazole | 52 | 37 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 47 | 22 |
| Mupirocin | Mupirocin | 47 | 38 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 47 | 31 |
| Chlorthalidone | Chlorthalidone | 46 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 46 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 45 | 12 |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 45 | 44 |
| Metoclopramide Hcl | Metoclopramide Hcl | 45 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | 13 |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Methylprednisolone | Methylprednisolone | 44 | 35 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Bumetanide | Bumetanide | 42 | suppressed |
| Mirtazapine | Mirtazapine | 42 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 42 | suppressed |
| Primidone | Primidone | 40 | suppressed |
| Januvia | Sitagliptin Phosphate | 39 | suppressed |
| Methocarbamol | Methocarbamol | 38 | 18 |
| Fenofibrate | Fenofibrate | 37 | suppressed |
| Finasteride | Finasteride | 37 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Temazepam | Temazepam | 36 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 35 | suppressed |
| Ezetimibe | Ezetimibe | 34 | 11 |
| Jardiance | Empagliflozin | 34 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 33 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Sucralfate | Sucralfate | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Norethindron-Ethinyl Estradiol | Norethindrone Ac/Eth Estradiol | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 26 | suppressed |
| Progesterone | Progesterone, Micronized | 26 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | 18 |
| Latanoprost | Latanoprost | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Febuxostat | Febuxostat | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 13 |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Dutasteride | Dutasteride | 21 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 20 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Jantoven | Warfarin Sodium | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Peg-3350 And Electrolytes | Peg3350/Sod Sulf,bicarb,cl/Kcl | 19 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | 13 |
| Estring | Estradiol | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 16 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 16 | 11 |
| Irbesartan | Irbesartan | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Methadone Hcl | Methadone Hcl | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Valproic Acid | Valproic Acid | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | 11 |
| Ursodiol | Ursodiol | 13 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Zolmitriptan | Zolmitriptan | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Neurontin | Gabapentin | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $150.80 · 11 records | Exact Sciences Corporation | Cologuard Collection Kit, ELIQUIS, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, VOQUEZNA, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error